Loading...
•
Mar 31, 2022
ORIC Pharmaceuticals Q1 2022 Earnings Report
ORIC Pharmaceuticals reported financial results and operational updates
Key Takeaways
ORIC Pharmaceuticals reported its Q1 2022 financial results, highlighting progress in its pipeline of novel oncology candidates and the expectation to report initial data from three ongoing studies in the first half of 2023. The company's cash and investments are expected to fund its current operating plan into 2H 2024.
Three ongoing single agent Phase 1 programs, ORIC-533, ORIC-114, and ORIC-944, are expected to report initial data in 1H2023.
Preclinical data was presented at the 2022 AACR Annual Meeting.
Cash and investments totaled $256.2 million as of March 31, 2022.
The company expects its cash and investments to fund the current operating plan into 2H 2024.
Forward Guidance
ORIC anticipates initial Phase 1b data from ORIC-533, ORIC-114, and ORIC-944 in 1H 2023.
Positive Outlook
- ORIC-533: Initial Phase 1b data in 1H 2023
- ORIC-114: Initial Phase 1b data in 1H 2023
- ORIC-944: Initial Phase 1b data in 1H 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...